Navigation Links
Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
Date:6/28/2011

HAYWARD, Calif., June 28, 2011 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced  today the presentation of final 48-week results of a phase 2 clinical study of ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) for the treatment of type 2 diabetes at the American Diabetes Association's 71st Scientific Sessions in San Diego, California.

(Logo:  http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

Results of the phase 2 study, presented by Julio Rosenstock, M.D., Director of the Dallas Diabetes and Endocrine Center at Medical City and Clinical Professor of Medicine at the University of Texas Southwestern Medical School, demonstrated that patients receiving treatment with ITCA 650 experienced substantial and sustained reductions in HbA1c, fasting plasma glucose (FPG) and body weight during the 48 weeks of treatment at all doses. A starting dose of ITCA 650 20 mcg/day for weeks 1 through 12 provided improved glycemic control with the best tolerability profile. Subsequent transition to ITCA 650 doses of 40, 60 or 80 mcg/day led to statistically significant improvements in HbA1c, FPG and body weight after 24 and 48 weeks of treatment.  

"We are very encouraged by the robust results observed in this study and the high level of enthusiasm expressed by patients and investigators," said Kurt Graves, Executive Chairman of the Board of Directors of Intarcia. "ITCA 650 is a novel GLP-1 therapeutic approach for type 2 diabetes that holds new promise for many patients and physicians who want robust glucose reductions and a favorable weight profile without the trade-offs associated with having to start potentially life-long and frequent self-injections." Graves added, "ITCA 650 not only delivers sustained glycemic control and favorable weight effects but the breakthrough subcutaneous continuous delivery platform is being developed as just a once-
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
2. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
3. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
8. SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use
9. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
10. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
11. TGen and PBS-Bio presents 2 abstracts at AACR conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 A ... the NCATS rare-diseases portfolio " in Science ... new financing technique to reduce the risk associated ... and potentially unlock new levels of funding for ... product of a unique collaboration between scientists at ...
(Date:2/27/2015)... 2015 Immunovaccine Inc. (“Immunovaccine”) (TSX: ... today announced that the U.S. Food and Drug ... designation and Phase I clinical trials of the ... mutual co-development agreement signed with Gilead Life Sciences. ... for the DPX-Survivac. , “We have been in ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 27, 2015 FamilyFarms Group is pleased ... of State Line Farms, received the 2015 Tomorrow’s Top ... under the age of 35, who has demonstrated excellence ... honor to win the Tomorrow's Top Producer Horizon Award. ... the Top Producer Award and learning from their experiences. ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... ANGELES, Dec. 13 Give the person on your ... the form of a Magical Mystical,Pen by world-renowned artist, ... series of Magical Mystical Tour,abstracts, currently exhibited in the ... House Gallery in St. James, NY, through,January 11, 2008., ...
... be presented at San Antonio Breast Cancer Symposium, ... world,leader in the rapidly evolving field of molecular ... demonstrated the,prognostic power of its MammaPrint(R) breast cancer ... nodes. The data show that,MammaPrint(R) can accurately identify ...
... Patients treated with drug-eluting,stents must take a combination ... least one year, and possibly longer, after stent,implantation. ... update published,online today in the journals of the ... of Cardiology (ACC), and,American Heart Association (AHA). To ...
Cached Biology Technology:Artistic Magical Mystical Tours 2MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients 2MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients 3PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 2PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 3PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 4
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... of Biological Sciences has placed another piece in the puzzle ... and eggs get the right number of chromosomes. The ... half its chromosomes from each parent sperm and eggs ... humans have 23 pairs of 46 chromosomes: so our sperm ...
... -- Marsh plants, far from being passive wallflowers, are "secret ... odds of survival, says a team of scientists from Duke ... Scientists have long believed that the distribution of plants ... grow at different elevations because that,s where conditions like soil ...
... 2013 Annual Meeting of the Southeastern Branch of ... held March 3-6, 2013 at the Hilton Baton ... Hundreds of entomologists from Alabama, Arkansas, Florida, Georgia, ... will meet to discuss citrus greening disease, invasive ...
Cached Biology News:Clues to chromosome crossovers 2Marsh plants actively engineer their landscape 2
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... The miVac DNA is an ideal ... ,A centrifugal concentrator capable of removing water ... sample formats including tubes, microplates, vials and ... "work-horse" concentrator for the busy lab. ,The ...
... Brownlee Precision Model 440 incorporates four channels ... a friendly easy-to-use instrument. Each channel consists ... 8-pole Bessel lowpass filter, a highpass filter, ... controls. A control knob sets the amplifier ...
Biology Products: